Puma Biotechnology (PBYI) Announces Positive Outcome Of European Opposition Proceedings
2/7/2014 8:39:46 AM
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that the European Patent Office has upheld the claims in Puma’s licensed European patent (EP 1848414) which were being opposed by Boehringer Ingelheim International GmbH.
Help employers find you! Check out all the jobs and post your resume.
comments powered by